US IPR Meeting Spotlights Argentina

28 July 1996

At the Intellectual Property Conference of the Americas meeting in Los Angeles, the Pharmaceutical Research & Manufacturers of America and a Deputy US Trade Representative discussed some of the worst patent offenders, with the spotlight on Argentina.

A PhRMA spokesman told the Marketletter that discussion centered on what patent piracy does to industry and innovation and to the industry in Argentina, and what can be done to overcome it. Argentina has promised to put in force meaningful patent protection and this has not happened, he noted, putting lost drug sales in Argentina at $500 million a year.

Meantime, none of the member associations of the Latin American Association of Pharmaceutical Industries, Alifar, attended the conference. They had repeatedly requested positions as panelists in any plenary or breakout session, but the requests could not be accommodated, says Alifar secretary Mirta Levis.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight